Journal of Clinical Oncology, Vol 4, 74-79, Copyright © 1986 by American Society of Clinical Oncology

ARTICLES

Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity

RP Warrell Jr and E Berman

Fludarabine phosphate (9-beta-D-arabinofuranosyl-2-fluoroadenine), a novel purine nucleoside, has demonstrated excellent preclinical antitumor activity and little toxicity in phase I clinical trials. We evaluated the clinical use of fludarabine given as a continuous intravenous (IV) infusion for remission induction in patients with relapsed or refractory leukemia. Thirty infusions were administered to 25 patients. At doses less than or equal to 125 mg/m2/d for five days, only three of 17 patients cleared their bone marrow of leukemic cells, and none achieved complete remission (CR). Nine patients received doses of 150 mg/m2/d for five days or 125 mg/m2/d for seven days. Four of these patients achieved CR (three patients with acute nonlymphoblastic leukemia (ANLL), one patient with acute lymphoblastic leukemia (ALL]. However, severe CNS toxicity was encountered in five patients at the two highest dose levels. Initial symptoms of neurotoxicity were delayed from 21 to 43 days after starting treatment and consisted of optic neuritis, cortical blindness, altered mental status, and generalized seizure. Only one patient regained visual and neurologic function; four other patients experienced progressive neurologic deterioration and died. Clinicopathologic evaluation suggested widespread, severe demyelination as the etiology of these reactions. We conclude that fludarabine is an effective drug for remission induction in acute leukemia. However, doses required to achieve CR are associated with unacceptable CNS toxicity. In view of its potent antileukemic activity, further evaluation of fludarabine at lower doses (less than or equal to 75 mg/m2/d for five days) may be warranted in combination with other chemotherapeutic agents for the treatment of patients with acute leukemia.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				H. Kantarjian, V. Gandhi, J. Cortes, S. Verstovsek, M. Du, G. Garcia-Manero, F. Giles, S. Faderl, S. O'Brien, S. Jeha, et al. Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia Blood, October 1, 2003; 102(7): 2379 - 2386. [Abstract] [Full Text] [PDF]

				M. Bornhauser, B. Storer, J. T. Slattery, F. R. Appelbaum, H. J. Deeg, J. Hansen, P. J. Martin, G. B. McDonald, W. G. Nichols, J. Radich, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells Blood, August 1, 2003; 102(3): 820 - 826. [Abstract] [Full Text] [PDF]

				H. M. Kantarjian, V. Gandhi, P. Kozuch, S. Faderl, F. Giles, J. Cortes, S. O'Brien, N. Ibrahim, F. Khuri, M. Du, et al. Phase I Clinical and Pharmacology Study of Clofarabine in Patients With Solid and Hematologic Cancers J. Clin. Oncol., March 15, 2003; 21(6): 1167 - 1173. [Abstract] [Full Text] [PDF]

				H. S. Hochster, M. M. Oken, J. N. Winter, L. I. Gordon, B. G. Raphael, J. M. Bennett, and P. A. Cassileth Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and and Long-Term Follow-Up--A Report From the Eastern Cooperative Oncology Group J. Clin. Oncol., March 1, 2000; 18(5): 987 - 987. [Abstract] [Full Text] [PDF]

				J. M. Foran, D. Oscier, J. Orchard, S. A. Johnson, M. Tighe, M. H. Cullen, P. G. de Takats, C. Kraus, M. Klein, and T. A. Lister Pharmacokinetic Study of Single Doses of Oral Fludarabine Phosphate in Patients With ""Low-Grade"" Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia J. Clin. Oncol., May 1, 1999; 17(5): 1574 - 1574. [Abstract] [Full Text] [PDF]

				J. M. Foran, A. Z.S. Rohatiner, B. Coiffier, T. Barbui, S. A. Johnson, W. Hiddemann, J. A. Radford, A. J. Norton, S. M. Tollerfield, M. P. Wilson, et al. Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenstrom's Macroglobulinemia, and Mantle-Cell Lymphoma J. Clin. Oncol., February 1, 1999; 17(2): 546 - 546. [Abstract] [Full Text] [PDF]

				J. M. Kolesar, A. K. Morris, and J. G. Kuhn Review : Purine nucleoside analogues: Fludarabine, pentostatin, and cladribine: Part 1: Fludarabine Journal of Oncology Pharmacy Practice, January 1, 1996; 2(3): 160 - 181. [Abstract] [PDF]

				R. B. Cohen, J. M. Abdallah, J. R. Gray, and F. Foss Reversible Neurologic Toxicity in Patients Treated with Standard-Dose Fludarabine Phosphate for Mycosis Fungoides and Chronic Lymphocytic Leukemia Ann Intern Med, January 15, 1993; 118(2): 114 - 116. [Abstract] [Full Text] [PDF]

				H. J. Durivage and N. L. Burnham Prevention and Management of Toxicities Associated With Antineoplastic Drugs Journal of Pharmacy Practice, January 1, 1991; 4(1): 27 - 48. [PDF]